Targets › CHRM4
4 programs from 2 companies in 13 trials: 7 Phase 3, 5 Phase 1, 1 Phase 2; Other, Psychiatry, Neurology; next expected readout Nov 2026.
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase. (UniProt, P08173)
Open in Phaseline: the race on CHRM4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Xanomeline Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist | CHRM4, CHRM1 | Phase 3 | Alzheimer Disease; Alzheimer's Disease; Healthy Volunteers; SCHIZOPHRENIA 1 (Disorder) | Mar 2027 |
| Bristol-Myers Squibb | Xanomeline (BMS-986519) Muscarinic acetylcholine receptor M4 agonist; Muscarinic acetylcholine receptor M1 agonist | CHRM4, CHRM1 | Phase 3 | Schizophrenia | Mar 2030 |
| AstraZeneca | Glycopyrronium Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor | CHRM3, CHRM1, CHRM4, CHRM2, CHRM5 | Phase 2 | Asthma | May 2029 |
| Bristol-Myers Squibb | BMS-986521 M4 muscarinic acetylcholine receptor antagonist | CHRM4 | Phase 1 | Healthy Volunteers | Nov 2026 |
Healthy Volunteers (4) Alzheimer Disease (3) Alzheimer's Disease (3) SCHIZOPHRENIA 1 (Disorder) (1) Schizophrenia (1) Asthma (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.